<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
   <ui>1750-9378-5-S1-A70</ui>
   <ji>1750-9378</ji>
   <fm>
      <dochead>Meeting abstracts</dochead>
      <bibl>
         <title>
            <p>Risk of anal cancer in HIV-infected patients and HIV-uninfected controls in North America</p>
         </title>
         <aug>
            <au id="A1" ca="yes">
               <snm>Silverberg</snm>
               <mi>J</mi>
               <fnm>Michael</fnm>
               <insr iid="I1"/>
               <email>Michael.J.Silverberg@kp.org</email>
            </au>
            <au id="A2">
               <snm>Lau</snm>
               <fnm>Bryan</fnm>
               <insr iid="I2"/>
            </au>
            <au id="A3">
               <snm>Jing</snm>
               <fnm>Yuezhou</fnm>
               <insr iid="I2"/>
            </au>
            <au id="A4">
               <snm>D&#8217;Souza</snm>
               <fnm>Gypsyamber</fnm>
               <insr iid="I2"/>
            </au>
            <au id="A5">
               <snm>Engels</snm>
               <mi>A</mi>
               <fnm>Eric</fnm>
               <insr iid="I3"/>
            </au>
            <au id="A6">
               <snm>Gill</snm>
               <fnm>John</fnm>
               <insr iid="I4"/>
            </au>
            <au id="A7">
               <snm>Goedert</snm>
               <mi>J</mi>
               <fnm>James</fnm>
               <insr iid="I3"/>
            </au>
            <au id="A8">
               <snm>Kirk</snm>
               <mi>D</mi>
               <fnm>Gregory</fnm>
               <insr iid="I2"/>
               <insr iid="I5"/>
            </au>
            <au id="A9">
               <snm>Justice</snm>
               <fnm>Amy</fnm>
               <insr iid="I6"/>
               <insr iid="I7"/>
            </au>
            <au id="A10">
               <snm>Dubrow</snm>
               <fnm>Robert</fnm>
               <insr iid="I6"/>
               <insr iid="I7"/>
            </au>
         </aug>
         <insg>
            <ins id="I1">
               <p>Kaiser Permanente Northern California, Oakland, CA, USA </p>
            </ins>
            <ins id="I2">
               <p>Johns Hopkins School of Public Health, Baltimore, MD, USA </p>
            </ins>
            <ins id="I3">
               <p>National Cancer Institute, Rockville, MD, USA </p>
            </ins>
            <ins id="I4">
               <p>University of Calgary, Calgary, Alberta, Canada </p>
            </ins>
            <ins id="I5">
               <p>Johns Hopkins School of Medicine, Baltimore, MD, USA </p>
            </ins>
            <ins id="I6">
               <p>Yale School of Public Health, New Haven, CT, USA </p>
            </ins>
            <ins id="I7">
               <p>Yale School of Medicine, New Haven, CT, USA </p>
            </ins>
         </insg>
         <source>Infectious Agents and Cancer</source>
         <supplement>
            <title>
               <p>Proceedings of the 12<sup>th</sup> International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI)</p>
            </title>
            <note>Meeting abstracts - A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1750-9378-5-S1-full.pdf">here</a>.</note>
            <url>http://www.biomedcentral.com/content/pdf/1750-9378-5-S1-info.pdf</url>
         </supplement>
         <conference>
            <title>
               <p>12<sup>th</sup> International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI)</p>
            </title>
            <location>Bethesda, MD, USA</location>
            <date-range>26-27 April, 2010</date-range>
            <url>http://oham.cancer.gov/</url>
         </conference>
         <issn>1750-9378</issn>
         <pubdate>2010</pubdate>
         <volume>5</volume>
         <issue>Suppl 1</issue>
         <fpage>A70</fpage>
         <url>http://www.infectagentscancer.com/content/5/S1/A70</url>
         <xrefbib>
            <pubid idtype="doi">10.1186/1750-9378-5-S1-A70</pubid>
         </xrefbib>
      </bibl>
      <history>
         <pub>
            <date>
               <day>11</day>
               <month>10</month>
               <year>2010</year>
            </date>
         </pub>
      </history>
      <cpyrt>
         <year>2010</year>
         <collab>Silverberg et al; licensee BioMed Central Ltd.</collab>
      </cpyrt>
   </fm>
   <bdy>
      <sec>
         <st>
            <p>Background</p>
         </st>
         <p>Studies have provided conflicting data for calendar trends in anal cancer among HIV+ individuals, one of the most frequent cancers in this population. Our objective here was to compare the risk of anal cancer between HIV+ and HIV- individuals in North America, and how this relationship has changed over time. </p>
      </sec>
      <sec>
         <st>
            <p>Methods</p>
         </st>
         <p>We conducted a cohort study involving 12 cohorts from North America followed between 1996 and 2007. Anal cancer incidence rates were compared between HIV+ men who have sex with men (MSM), HIV+ non-MSM (including women), and HIV- individuals. We calculated rate ratios (RRs) using multivariable Poisson regression with adjustment for age, sex, race/ethnicity (26% imputed), and calendar era. We next determined whether the adjusted RR for HIV+ compared with HIV- controls has changed over time. Since only a subset of cohorts contributed HIV- controls, we also computed age- and sex- and race-standardized incidence ratios (SIR) using national U.S. SEER rates. </p>
      </sec>
      <sec>
         <st>
            <p>Results</p>
         </st>
         <p>Cohort-specific HIV+ anal cancer incidence rates ranged across cohorts from 0 to 154 cases per 100,000 person-years. The cohort-specific prevalence of MSM explained 58% of the total variability in rates. Overall, there were 111 anal cancer diagnoses among 15,907 HIV+ MSM, 38 diagnoses among 18,239 HIV+ non-MSM, and 79 diagnoses among 115,469 HIV- individuals. The corresponding adjusted RRs were 66.6 (95% CI: 36.9-120.2) for HIV+ MSM and 23.4 (95% CI: 11.9-46.1) for HIV+ non-MSM compared with the HIV- control group. For both HIV+ MSM and non-MSM, the RR was highest in 1999-2002, but the RR decreased for both groups in the most recent calendar era, 2003-2007 (Table <tblr tid="T1">1</tblr>), although the differences were not statistically significant (p>0.2) comparing RRs across eras. Inferences were similar for SIRs.</p>
         <tbl id="T1">
            <title>
               <p>Table 1</p>
            </title>
            <caption>
               <p>Anal cancer RR (95% CI) for HIV+ MSM and HIV+ non-MSM compared with HIV- controls (reference) and national US SEER rates.</p>
            </caption>
            <tblbdy cols="5">
               <r>
                  <c>
                     <p/>
                  </c>
                  <c>
                     <p>
                        <b>RR (MSM)</b>
                     </p>
                  </c>
                  <c>
                     <p>
                        <b>RR (non-MSM)</b>
                     </p>
                  </c>
                  <c>
                     <p>
                        <b>SIR (MSM)</b>
                     </p>
                  </c>
                  <c>
                     <p>
                        <b>SIR (non-MSM)</b>
                     </p>
                  </c>
               </r>
               <r>
                  <c cspan="5">
                     <hr/>
                  </c>
               </r>
               <r>
                  <c>
                     <p>1996 to 1998</p>
                  </c>
                  <c>
                     <p>97.7 (12.3-774.3)</p>
                  </c>
                  <c>
                     <p>12.0 (0.7-195.5)</p>
                  </c>
                  <c>
                     <p>63.5 (29.0-120.6)</p>
                  </c>
                  <c>
                     <p>10.2 (0.3-56.9)</p>
                  </c>
               </r>
               <r>
                  <c>
                     <p>1999 to 2002</p>
                  </c>
                  <c>
                     <p>114.7 (35.3-372.8)</p>
                  </c>
                  <c>
                     <p>35.2 (9.8-126.5)</p>
                  </c>
                  <c>
                     <p>117.3 (84.5-158.5)</p>
                  </c>
                  <c>
                     <p>26.4 (11.4-52.0)</p>
                  </c>
               </r>
               <r>
                  <c>
                     <p>2003 to 2007</p>
                  </c>
                  <c>
                     <p>48.1 (23.6-98.2)</p>
                  </c>
                  <c>
                     <p>19.7 (8.8-44.1)</p>
                  </c>
                  <c>
                     <p>77.7 (59.3-100.0)</p>
                  </c>
                  <c>
                     <p>26.4 (14.8-43.5)</p>
                  </c>
               </r>
            </tblbdy>
         </tbl>
      </sec>
      <sec>
         <st>
            <p>Conclusions</p>
         </st>
         <p>Despite an aging HIV+ population with presumed longer exposure to the oncogenic effects of human papillomavirus, the relative incidence of anal cancer among HIV+ individuals in the most recent calendar era has not increased. It is possible that improvements in immune function resulting from effective antiretroviral therapy contributed to this result.</p>
      </sec>
   </bdy>
   <bm>
      <ack>
         <sec>
            <st>
               <p>Acknowledgements</p>
            </st>
            <p>The abstract is submitted on behalf of the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).</p>
            <p>This article has been published as part of <it>Infectious Agents and Cancer</it> Volume 5 Supplement 1, 2010: Proceedings of the 12<sup>th</sup> International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI).The full contents of the supplement are available online at <url>http://www.biomedcentral.com/1750-9378/5?issue=S1</url>.</p>
         </sec>
      </ack>
   </bm>
</art>
